Transient receptor potential channel activation targets multiple stages of the schistosome parasite.

M5493, a novel drug targeting a parasite TRP channel, effectively treats multiple stages of Schistosoma mansoni at low doses in mice.

• Why it matters: Current reliance on praziquantel limits options and risks drug resistance, highlighting the urgent need for new, broad-spectrum treatments that can prevent and cure schistosomiasis.
• What they did: Researchers developed M5493, a prodrug with potent activity against various parasite life cycle stages, by targeting a distinct TRP ion channel, and tested it in infected mice at doses as low as 5 mg/kg.
• The result: M5493 demonstrated strong anti-parasitic effects without sedative side effects, offering potential for single-dose, transmission-blocking therapy that could improve disease control and reduce resistance.